AcquisitionOther
Amphastar Pharmaceuticals, Inc. acquired BAQSIMI
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Amphastar Pharmaceuticals, Inc. -> BAQSIMI · $500 million
● Builds upon Amphastar’s commercial intranasal product portfolio.
Open source record (SEC) ↗